

## IN THE CLAIMS

The following is a listing of claims in the application:

Claims 1-21 (cancelled)

Claim 22 (Previously presented): An isolated *Listeria monocytogenes* bacterium which comprises:

(a) a deletion in the genomic *actA* and *inlB* genes of the bacterium whereby the bacterium does not express ActA or InlB proteins;

(b) a functional genomic *inlA* gene whereby the bacterium expresses InlA protein; and

(c) a nucleic acid sequence encoding a non-*Listerial* polypeptide operably linked to a promoter sequence directing expression of the polypeptide whereby the bacterium expresses the non-*Listerial* polypeptide.

Claims 23-37 (cancelled)

Claim 38 (Previously presented): A composition comprising (a) the *Listeria* bacterium of claim 22, and (b) an adjuvant.

Claim 39 (Previously presented): A method of inducing an immune response in a host to a non-*Listerial* antigen comprising administering to the host an effective amount of a composition comprising the *Listeria* bacterium of claim 22, wherein the non-*Listerial* polypeptide comprises the non-*Listerial* antigen.

Claim 40 (Previously presented): A method of expressing a non-*Listerial* polypeptide in a host, comprising administering to the host an effective amount of a composition comprising the *Listeria* bacterium of claim 22 expressing the non-*Listerial* polypeptide.

Claim 41 (Previously presented): An isolated professional antigen-presenting cell comprising the *Listeria* bacterium of claim 22.

Claims 42-75 (cancelled)

Claim 76 (Previously presented): The method of claim 40, wherein the host is selected on the basis of a diagnosis of cancer in the host.

Claim 77 (Previously presented). The method of claim 40, wherein the host is selected on the basis of a need for protection against a disease in the host.

Claims 78-80 (cancelled)

Claim 81 (Previously presented): The method of claim 77, wherein the disease is an infectious disease.

Claim 82 (Previously presented): The method of claim 77, wherein the disease is cancer.

Claim 83 (Previously presented): A pharmaceutical composition comprising (a) the *Listeria* bacterium of claim 22, and (b) a pharmaceutically acceptable carrier.

Claims 84-89 (cancelled)

Claim 90 (Previously presented): The method of claim 40, wherein the host is selected on the basis of a diagnosis of an infectious disease in the host.

Claims 91-110 (cancelled)